3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

Journal of Crohn's and Colitis

Volumn 5, Issue 2, 2011, Pages 129-138

  Gross, Volker ^a   Bunganic, Ivan ^b   Belousova, Elena A ^c   Mikhailova, Tatyana L ^d   Kupcinskas, Limas ^e   Kiudelis, Gediminas ^e   Tulassay, Zsolt ^f   Gabalec, Libor ^g   Dorofeyev, Andrey E ^h   Derova, Jelena ⁱ   Dilger, Karin ^j   Greinwald, Roland ^j   Mueller, Ralph ^j  

^a KLINIKUM ST MARIEN   (Germany)

^b MUCO Gastroenterologická ambulancia ^*  (Slovakia)

^c M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^d State Scientific Centre of Coloproctology   (Russian Federation)

^e KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^g Nemocnice v Ústi nad Orlicí   (Czech Republic)

^h DONETSK MEDICAL UNIVERSITY   (Ukraine)

ⁱ Latvian Maritime Medical Centre   (Latvia)

^j Alcon Pharma GmbH   (Germany)

more..

Author keywords

Budesonide; Mesalazine; Randomised clinical trial; Remission; Ulcerative colitis

Indexed keywords

BUDENOFALK; BUDESONIDE; MESALAZINE; PLACEBO;

ACNE; ADULT; AGED; APPENDICITIS; ARTICLE; CHOLESTATIC HEPATITIS; CHRONIC PANCREATITIS; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FECES; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUDESONIDE; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; KAPLAN-MEIER ESTIMATE; MALE; MESALAMINE; MIDDLE AGED; REMISSION INDUCTION;

EID: 79953085950     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.11.006     Document Type: Article

References (48)

1. Regueiro M., Loftus E.V.J., Steinhart A.H.M., Cohen R.D.M. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979-994.
2. Bayless T., Sninsky C. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis [abstract]. Gastroenterology 1995, 108(4, Suppl.):A778. US budesonide study group.
3. Danielsson A., Löfberg R., Persson T., Salde L., Schioler R., Suhr O., et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992, 27:9-12.
4. Hanauer S.B., Robinson M., Pruitt R., Lazenby A.J., Persson T., Nilsson L.G., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998, 115:525-532.
5. Lamers C., Meijer J., Engels L., Bos L., van Hogezand R.A., Driessen W.M.M., et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis [abstract]. Gastroenterology 1991, 100(5, Suppl. 2):A223.
6. Lémann M., Galian A., Rutgeerts P., Van Heuverzwijn R., Cortot A., Viteau J.M., et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995, 9:557-562.
7. Bianchi-Porro G., Prantera C., Campieri M., Petrillo M., Campanini M.C., Gionchetti P. Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994, 6:125-130.
8. Danielsson A., Hellers G., Lyrenas E., Lofberg R., Nilsson A., Olsson O., et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987, 22:987-992.
9. Löfberg R., Ostergaard T.O., Langholz E., Schioler R., Danielsson A., Suhr O., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994, 8:623-629.
10. Tarpila S., Turunen U., Seppala K., Aukee S., Pikkarainen P., Elomaa I., et al. Budesonide enema in active haemorrhagic proctitis - a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 1994, 8:591-595.
11. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol 1991, 26:1225-1230. The Danish budesonide study group.
12. Hammond A., Andus T., Gierend M., Ecker K.W., Schölmerich J., Herfarth H. the German Budesonide Foam Study group. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepatogastroenterology 2004, 51:1345-1349.
13. Bar-Meir S., Fidder H.H., Faszczyk M., Bianchi P.G., Sturniolo G.C., Mickisch O., et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003, 46:929-936.
14. Gross V., Bar-Meir S., Lavy A., Mickisch O., Tulassay Z., Pronai L., et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006, 23:303-312.
15. Angelucci E., Malesci A., Danese S. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr Med Chem 2008, 15:2527-2535.
16. Gross V. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis. Expert Opin Pharmacother 2008, 9:1257-1265.
17. Travis S.P.L., Stange E.F., Lemann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006, 55:i16-i35.
18. Chande N., Macdonald J.K., McDonald J.W. Interventions for treating microscopic colitis: a cochrane inflammatory bowel disease and functional bowel disorders review group systematic review of randomized trials. Am J Gastroenterol 2009, 104:235-241.
19. Baert F., Schmit A., D'Haens G., Dedeurwaerdere F., Louis E., Cabooter M., et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002, 122:20-25.
20. Bonderup O.K., Hansen J.B., Birket-Smith L., Vestergaard V., Teglbjaerg P.S., Fallingborg J. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 2003, 52:248-251.
21. Bonderup O.K., Hansen J.B., Teglbjoerg P.S., Christensen L.A., Fallingborg J.F. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009, 58:68-72.
22. Miehlke S., Heymer P., Bethke B., Bastlein E., Meier E., Bartram H.P., et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002, 123:978-984.
23. Miehlke S., Madisch A., Bethke B., Morgner A., Kuhlisch E., Henker C., et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008, 135:1510-1516.
24. Miehlke S., Madisch A., Karimi D., Wonschik S., Kuhlisch E., Beckmann R., et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009, 136:2092-2100.
25. Pardi D.S., Loftus E.V., Tremaine W.J., Sandborn W.J. Abstract. Gastroenterology 2009, 136(Suppl 1):T1193.
26. Kao K.T., Pedraza B.A., McClune A.C., Rios D.A., Mao Y.Q., Zuch R.H., et al. Microscopic colitis: a large retrospective analysis from a health maintenance organization experience. World J Gastroenterol 2009, 15:3122-3127.
27. Edsbacker S., Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004, 43:803-821.
28. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990, 4:407-414.
29. Bar-Meir S., Chowers Y., Lavy A., Abramovitch D., Sternberg A., Leichtmann G., et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998, 115:835-840.
30. Rutgeerts P., Lofberg R., Malchow H., Lamers C., Olaison G., Jewell D., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845.
31. D'Haens G.R., Kovacs A., Vergauwe P., Nagy F., Molnar T., Bouhnik Y., et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohn Colitis 2010, 4:153-160.
32. Kolkman J.J., Möllmann H.W., Möllmann A.C., Pena A.S., Greinwald R., Tauschel H.D., et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today 2004, 40:589-601.
33. Löfberg R., Danielsson A., Suhr O., Nilsson A., Schioler R., Nyberg A., et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110:1713-1718.
34. Keller R., Stoll R., Foerster E.C., Gutsche N., Domschke W. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997, 11:1047-1052.
35. Moss A.C., Peppercorn M.A. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007, 6:99-107.
36. Travis S.P.L., Stange E.F., Lémann M., Oresland T., Bempelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008, 2:24-62.
37. Brunner M., Greinwald R., Kletter K., Kvaternik H., Corrado M.E., Eichler H.G., et al. Gastrointestinal transit and release of 5-aminosalicylic acid from (15)Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003, 17:1163-1169.
38. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
39. Riley S.A., Mani V., Goodman M.J., Dutt S., Herd M.E. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
40. Hanauer S.B., Schwartz J., Robinson M., Roufail W., Arora S., Cello J., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993, 88:1188-1197.
41. EMEA CPMP/EWB/18463/2006 (FINAL): Guideline on the development of new medicinal products for the treatment of ulcerative colitis 2008, EMEA, London.
42. Kruis W., Kiudelis G., Racz I., Gorelov I.A., Pokrotnieks J., Horynski M., et al. Once-daily versus three-times-daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised non-inferiority trial. Gut 2009, 58:233-240. 10.1136/gut.2008.154302.
43. Kruis W., Bar-Meir S., Feher J., Mickisch O., Mlitz H., Faszczyk M., et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003, 1:36-43.
44. Marakhouski Y., Fixa B., Holoman J., Hulek P., Lukas M., Batovsky M., et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005, 21:133-140.
45. Möllmann H.W., Barth J., Hochhaus G., Möllmann A.C., Derendorf H., Tromm A. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. International Falk Workshop 73B: Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease - From Basic Principles to Rational Therapy 1996, 42-60. Kluwer Academic Publishers, Dortrecht, Boston, London. H.W. Möllmann, B. May (Eds.).
46. Herfarth H., Gross V., Andus T., Caesar I., Vogelsang H., Adler G., et al. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis 2004, 19:147-152.
47. Tromm A., Bunganic I., Tomsova E., Tulassay Z., Lukas M., Kykal J., et al. Budesonide (9mg) is at least as effective as mesalamine (4.5g) in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011, 140:425-434.
48. Su C., Lewis J.D., Goldberg B., Brensinger C., Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007, 132:516-526.